Oyster Point Pharma, Inc. (OYST) has an overall financial health rating of B- with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2023-02-03.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2023-02-03 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-02-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-02-01 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-01-31 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-01-30 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-01-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-01-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-01-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-01-23 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-01-19 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-01-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-01-17 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
